These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 31916540)

  • 1. The role of cannabinoids in epilepsy treatment: a critical review of efficacy results from clinical trials.
    Nabbout R; Thiele EA
    Epileptic Disord; 2020 Jan; 22(S1):23-28. PubMed ID: 31916540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results.
    Laux LC; Bebin EM; Checketts D; Chez M; Flamini R; Marsh ED; Miller I; Nichol K; Park Y; Segal E; Seltzer L; Szaflarski JP; Thiele EA; Weinstock A;
    Epilepsy Res; 2019 Aug; 154():13-20. PubMed ID: 31022635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cannabinoids in treatment-resistant epilepsy: A review.
    O'Connell BK; Gloss D; Devinsky O
    Epilepsy Behav; 2017 May; 70(Pt B):341-348. PubMed ID: 28188044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox-Gastaut Syndrome.
    Lattanzi S; Trinka E; Striano P; Rocchi C; Salvemini S; Silvestrini M; Brigo F
    CNS Drugs; 2021 Mar; 35(3):265-281. PubMed ID: 33754312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The proposed mechanisms of action of CBD in epilepsy.
    Gray RA; Whalley BJ
    Epileptic Disord; 2020 Jan; 22(S1):10-15. PubMed ID: 32053110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Source of cannabinoids: what is available, what is used, and where does it come from?
    Specchio N; Pietrafusa N; Cross HJ
    Epileptic Disord; 2020 Jan; 22(S1):1-9. PubMed ID: 31941643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox-Gastaut syndrome.
    Hussain SA; Zhou R; Jacobson C; Weng J; Cheng E; Lay J; Hung P; Lerner JT; Sankar R
    Epilepsy Behav; 2015 Jun; 47():138-41. PubMed ID: 25935511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cannabidiol Therapy for Refractory Epilepsy and Seizure Disorders.
    Golub V; Reddy DS
    Adv Exp Med Biol; 2021; 1264():93-110. PubMed ID: 33332006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cannabis for the Treatment of Epilepsy: an Update.
    Gaston TE; Szaflarski JP
    Curr Neurol Neurosci Rep; 2018 Sep; 18(11):73. PubMed ID: 30194563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic and clinical foundations of cannabidiol therapy for difficult-to-treat seizures in children and adults with refractory epilepsies.
    Reddy DS
    Exp Neurol; 2023 Jan; 359():114237. PubMed ID: 36206806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Consensus panel recommendations for the optimization of EPIDIOLEX® treatment for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex.
    Wechsler RT; Burdette DE; Gidal BE; Hyslop A; McGoldrick PE; Thiele EA; Valeriano J
    Epilepsia Open; 2024 Oct; 9(5):1632-1642. PubMed ID: 39007525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cannabidiol as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome.
    Lattanzi S; Trinka E; Russo E; Striano P; Citraro R; Silvestrini M; Brigo F
    Drugs Today (Barc); 2019 Mar; 55(3):177-196. PubMed ID: 30938373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis.
    Talwar A; Estes E; Aparasu R; Reddy DS
    Exp Neurol; 2023 Jan; 359():114238. PubMed ID: 36206805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epilepsy and cannabidiol: a guide to treatment.
    Arzimanoglou A; Brandl U; Cross JH; Gil-Nagel A; Lagae L; Landmark CJ; Specchio N; Nabbout R; Thiele EA; Gubbay O; The Cannabinoids International Experts Panel ;
    Epileptic Disord; 2020 Feb; 22(1):1-14. PubMed ID: 32096470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrospective chart review study of use of cannabidiol (CBD) independent of concomitant clobazam use in patients with Lennox-Gastaut syndrome or Dravet syndrome.
    Nabbout R; Arzimanoglou A; Auvin S; Berquin P; Desurkar A; Fuller D; Nortvedt C; Pulitano P; Rosati A; Soto V; Villanueva V; Cross JH
    Seizure; 2023 Aug; 110():78-85. PubMed ID: 37331197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world evidence on the use of cannabidiol for the treatment of drug resistant epilepsy not related to Lennox-Gastaut syndrome, Dravet syndrome or Tuberous Sclerosis Complex.
    Espinosa-Jovel C; Riveros S; Bolaños-Almeida C; Salazar MR; Inga LC; Guío L
    Seizure; 2023 Nov; 112():72-76. PubMed ID: 37769547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.
    Devinsky O; Marsh E; Friedman D; Thiele E; Laux L; Sullivan J; Miller I; Flamini R; Wilfong A; Filloux F; Wong M; Tilton N; Bruno P; Bluvstein J; Hedlund J; Kamens R; Maclean J; Nangia S; Singhal NS; Wilson CA; Patel A; Cilio MR
    Lancet Neurol; 2016 Mar; 15(3):270-8. PubMed ID: 26724101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological and Therapeutic Properties of Cannabidiol for Epilepsy.
    Franco V; Perucca E
    Drugs; 2019 Sep; 79(13):1435-1454. PubMed ID: 31372958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cannabidiol in conjunction with clobazam: analysis of four randomized controlled trials.
    Gunning B; Mazurkiewicz-Bełdzińska M; Chin RFM; Bhathal H; Nortvedt C; Dunayevich E; Checketts D
    Acta Neurol Scand; 2021 Feb; 143(2):154-163. PubMed ID: 32969022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Caregiver-reported outcomes with real-world use of cannabidiol in Lennox-Gastaut syndrome and Dravet syndrome from the BECOME survey.
    Berg AT; Dixon-Salazar T; Meskis MA; Danese SR; Le NMD; Perry MS
    Epilepsy Res; 2024 Feb; 200():107280. PubMed ID: 38183688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.